Three AstraZeneca patents ruled invalid in Australia

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

The court's decision only affects the patent in Australia and does not have an impact on the validity of patents related to Crestor in any other country.

Total sales of Crestor in Australia for 2012 were approximately $350m.

In a statement the group said: "AstraZeneca is disappointed in the court's decision to find these patents invalid. The company remains committed to defending its intellectual property protecting Crestor in Australia and is carefully reviewing this decision and evaluating all legal options at this time, which could include filing an appeal and seeking to maintain existing preliminary injunctions."

Of the patents, one was a formulation patent, the second was related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (high cholesterol), and the third was related to the use of rosuvastatin for treating hypercholesterolemia.

The share price was up 0.47% to 3,022p by 09:05.

NR

Recommended

HubSpot: a tech stock set to tumble
Trading

HubSpot: a tech stock set to tumble

US tech stocks have had a fantastic couple of years. But this year is unlikely to be so bullish for high-fliers that can’t turn big profits.
18 Jan 2022
How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022

Most Popular

Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
US inflation is at its highest since 1982. Why aren’t markets panicking?
Inflation

US inflation is at its highest since 1982. Why aren’t markets panicking?

US inflation is at 7% – the last time it was this high interest rates were at 14%. But instead of panicking, markets just shrugged. John Stepek explai…
13 Jan 2022
Tech stocks teeter as US Treasury bond yields rise
Tech stocks

Tech stocks teeter as US Treasury bond yields rise

The realisation that central banks are about to tighten their monetary policies caused a sell-off in the tech-heavy Nasdaq stock index and the biggest…
14 Jan 2022